PTO/SB/68 (07-03)

Approved for use through 7/31/2003. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

REQUEST FOR ACCESS TO AN ABANDONED APPLICATION UNDER 37 CFR 1.14	
	In re Application of
Bring completed form to: File Information Unit Crystal Plaza Three, Room 1001 2021 South Clark Place Arlington, VA Telephone: (703) 308-2733 APR 0 2 2004 I hereby request access under 37 CFR 1.14(a)(1)(iv) to the	Application Number O7 99 8114 Paper No. ##25
application, which is identification, on to which अनुसार is c attachment):	claimed, in the following document (as shown in the
United States Patent Application Publication No.	, page, line,
United States Patent Number 5541216.	column, line, or
WIPO Pub. No, page	, line
Related Information about Access to Pendin Direct access to pending applications is not available to purchased from the Office of Public Records upon paymer For published applications that are still pending, a member the file contents; the pending application as originally filed; or any document in the file of the pending application. For unpublished applications that are still pending: (1) If the benefit of the pending application is claimed unapplication that has: (a) issued as a U.S. patent, or (patent application publication, or an international pate Article 21(2), a member of the public may obtain a contents; the pending application as originally filed; or any document in the file of the pending application, and document in the file of the pending application, and accordance with PCT Article 21(2), a member of the the pending application as originally filed. Signature Registration Number, if applicable Registration Number, if applicable Telephone Number	to the public but copies may be available and may be not of the appropriate fee (37 CFR 1.19(b)), as follows: er of the public may obtain a copy of: Index 35 U.S.C. 119(e), 120, 121, or 365 in another (b) published as a statutory invention registration, a U.S. tent application publication in accordance with PCT opy of: ation. Exercise identified in a U.S. patent, a statutory invention an international patent application publication in

This collection of information is required by 37 CFR 1.14. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. BRING TO: File Information Unit, Crystal Plaza Three, Room 1001, 2021 South Clark Place, Arlington, VA.

United States Patent [19]

Kempf et al.

Patent Number: . [11]

5,541,206

Date of Patent: [45]

Jul. 30, 1996

[54] RETROVIRAL PROTEASE INHIBITING **COMPOUNDS**

[75] Inventors: Dale J. Kempf, Libertyville: Daniel W. Norbeck, Crystal Lake; Hing Leung Sham; Chen Zhao, both of Gurnee, all

[73] Assignee: Abbott Laboratories, Abbott Park, Ill.

[21] Appl. No.: 423,387

[22] Filed: Apr. 25, 1995

Related U.S. Application Data

[63] [Continuation of Ser. No. 158,587, Dec. 2, 1993, abandoned. which is a continuation-in-part of Ser. No. 998,114, Dec. 29, 1992, abandoned, which is a continuation-in-part of Ser. No. 777,626, Oct. 23, 1991, abandoned which is a continuation-in-part of Ser. No. 746,020; Aug. 15, 1991, abandoned, which is a continuation-in-part of Ser. No. 616,170, Nov. 20, 1990, abandoned (which is a continuation-in-part of Ser. No. 518,730, May 9, 1990, Par. No. 5,142,056, which is a continuation-in-part of Ser. No. 456,124, Dec. 22, 1989, abandoned, which is a continuation-in-part of Ser. No. 405,604, Sep. 8, 1989, abandoned, which is a continuation-in-part of Ser. No. 355,945, May 23, 1989, abandoned. which is a continuation-in-part of Ser. No. 998,114, Dec. 29,

[51] C07D 417/12

548/187; 548/235; 548/227; 548/228; 548/229; 514/374; 514/369; 514/370; 514/376; 514/377

514/369, 370, 376, 377; 548/204, 194, 187, 235, 227, 228, 229

. [56] References Cited

U.S. PATENT DOCUMENTS

5,354,866 10/1994 Kempf et al.

FOREIGN PATENT DOCUMENTS

346847B1 12/1989 European Pat. Off. .

393445B2a 10/1990 European Pat. Off. .

393445B2 10/1990 European Pat. Off. .

402646B6 12/1990 European Pat. Off. .

428B49B12 5/1991 European Pat. Off. European Pat. Off. . 428849B12a 5/1991 441192B3 8/1991 European Pat. Off. . 441192B3a European Pat. Off. . 8/1991 486948B5 5/1992 European Pat. Off. . 3829594B1a 3/1990 Germany . 3829594B1 3/1990 Germany . 4003575B4 8/1992 Germany . 4003575B4s 8/1992 Germany . W088/ 02374B7 4/1988 WIPO . WO92/ 00948B9 8/1990 W090/ 09191B8a 8/1990 WIPO. WO90/ 0919188 8/1990-W091/ 12/1991 18866B10 W092/ 06996B11 4/1992 "WIPO WO92/ 20665B13 11/1992 WIPO WQ93/ 01174B14 1/1993 WIPO. OTHER PUBLICATIONS

Wade Jr. Organic Chemistry p. 349 1987 by Prentice-Hall.

Zeffren et al. The Study of Enzyme Mechanism, p. 87, 1974. Shutske et al. J. Med. Chem. 1989, 32, 1805-1813,

Primary Examiner-Jane Fan Attorney, Agent, or Firm-Steven R. Crowley

ABSTRACT

A retroviral protease inhibiting compound of the formula-

$$\underset{R_{1}}{\overset{R_{3}}{\longleftarrow}}_{n} Z \overset{O}{\overset{R_{3}}{\longleftarrow}} \overset{R_{1}}{\overset{H}{\longleftarrow}} X \overset{R_{4_{n}}}{\overset{Q}{\longleftarrow}} \overset{O}{\underset{H}{\longleftarrow}} \overset{R_{5}}{\overset{R_{5}}{\longleftarrow}} \underset{R_{5}}{\overset{R_{5}}{\longleftarrow}} \overset{R_{5}}{\overset{R_{5}}{\longleftarrow}} \overset{R_{5}}{\overset{R_{5}}{\overset{R_{5}}{\longleftarrow}}} \overset{R_{5}}{\overset{R_{5}}{\overset{R_{5}}{\longleftarrow}}} \overset{R_{5}}{\overset{R_{5}}{\overset{R_{5}}{\longleftarrow}}} \overset{R_{5}}{\overset{R_{5}}{\overset{R_{5}}{\longleftarrow}}} \overset{R_{5}}{\overset{R_{5}}{\overset{R_{5}}{\longleftarrow}}} \overset{R_{5}}{\overset{R_{5}}{\overset{R_{5}}{\longleftarrow}}} \overset{R_{5}}{\overset{R_{5}}{\overset{R_{5}}{\longleftarrow}}} \overset{R_{5}}{\overset{R_{5}}{\overset{R_{5}}{\longleftarrow}}} \overset{R_{5}}{\overset{R_{5}}{\overset{R_{5}}{\longleftarrow}}} \overset{R_{5}}{\overset{R_{5}}{\overset{R_{5}}{\overset{R_{5}}{\longleftarrow}}} \overset{R_{5}}{\overset{R_{5}}{\overset{R_{5}}{\overset{R_{5}}{\longleftarrow}}} \overset{R_{5}}{\overset{R}}{\overset{R_{5}}{\overset{R_{5}}{\overset{R_{5}}{\overset{R_{5}}{\overset{R_{5}}{\overset{R_{5}}{\overset{R_{5}$$

is disclosed.

19 Claims, No Drawings